There is no evidence that DHEA  improves quality of life but there is some evidence that it is associated with and rogenic side effects .
There is uncertainty whether DHEA decreases menopausal symptoms , but DHEA may slightly improve sexual function compared with placebo
BACKGROUND During menopause a decreasing ovarian follicular response generally causes a fluctuation and eventual decrease in estrogen levels .
This can lead to the development of various perimenopausal and postmenopausal symptoms ( for example hot flushes , night sweats , vaginal dryness ) .
Dehydroepi and rosterone ( DHEA ) is one of the main precursors of and rogens , which in turn are converted to testosterone and estrogens .
It is possible that the administration of DHEA may increase estrogen and testosterone levels in peri- and postmenopausal women to alleviate their symptoms and improve general wellbeing and sexual function ( for example libido , dyspareunia , satisfaction ) .
Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety .
This review should clearly outline the evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of r and omised controlled trials .
OBJECTIVES To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri- or postmenopausal phase .
Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well-Ness (DAWN) Trial.
OBJECTIVES To examine the effects of dehydroepi and rosterone ( DHEA ) supplementation on cognitive function and quality of life in healthy older adults . DESIGN Double-blind , r and omized , controlled clinical trial . SETTING Clinical research facility . PARTICIPANTS One hundred ten men and 115 women aged 55 to 85 ( mean + /- st and ard deviation 68 + /- 8) . INTERVENTION Fifty milligrams daily oral DHEA versus placebo for 1 year . MEASUREMENTS Six cognitive function tests at baseline and 12 months , the Beck Depression Inventory ( BDI ) , the Medical Outcomes Study 36-item Short Form Survey ( SF-36 ) , the Life Satisfaction Index-Z , the Satisfaction with Life Scale , the Female Sexual Function Index ( in women ) , and the 15-item International Index of Erectile Function ( in men ) at baseline and 3 , 6 , and 12 months . RESULTS There were no differences between the DHEA and placebo groups in change over time in cognitive function ( P>.10 ) . Over time , BDI scores decreased for men ( P=.006 ) and women ( P=.02 ) , and Satisfaction with Life Scale scores increased for women ( P=.004 ) , but there were no differences between the DHEA and placebo groups over time on these measures or the SF-36 , Life Satisfaction Index-Z scale , or sexual function scales ( P>.10 ) . CONCLUSION DHEA supplementation has no benefit on cognitive performance or well-being in healthy older adults , and it should not be recommended for that purpose in the general population
There is no evidence that DHEA  improves quality of life but there is some evidence that it is associated with and rogenic side effects .
There is uncertainty whether DHEA decreases menopausal symptoms , but DHEA may slightly improve sexual function compared with placebo
BACKGROUND During menopause a decreasing ovarian follicular response generally causes a fluctuation and eventual decrease in estrogen levels .
This can lead to the development of various perimenopausal and postmenopausal symptoms ( for example hot flushes , night sweats , vaginal dryness ) .
Dehydroepi and rosterone ( DHEA ) is one of the main precursors of and rogens , which in turn are converted to testosterone and estrogens .
It is possible that the administration of DHEA may increase estrogen and testosterone levels in peri- and postmenopausal women to alleviate their symptoms and improve general wellbeing and sexual function ( for example libido , dyspareunia , satisfaction ) .
Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety .
This review should clearly outline the evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of r and omised controlled trials .
OBJECTIVES To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri- or postmenopausal phase .